It is worth noting that even though the cardioprotective efficacy of SGLT2 inhibitors is well established and also confirmed in patients with glomerulonephritis, this subset of patients has a low burden of cardiovascular disease. This evidence concerns the gene SLC5A2 and glomerulonephritis.